Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.

@article{Karron2005IdentificationOA,
  title={Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.},
  author={Ruth A. Karron and Peter Farnum Wright and Robert B. Belshe and Bhagvanji Thumar and Roberta Casey and Frances Newman and Fernando P Polack and Valerie B Randolph and Anne M. Deatly and Jill G Hackell and William C. Gruber and Brian R. Murphy and Peter L. Collins},
  journal={The Journal of infectious diseases},
  year={2005},
  volume={191 7},
  pages={1093-104}
}
BACKGROUND Recombination technology can be used to create live attenuated respiratory syncytial virus (RSV) vaccines that contain combinations of known attenuating mutations. METHODS Two live attenuated, recombinantly derived RSV vaccine candidates, rA2cp248/404 Delta SH and rA2cp248/404/1030 Delta SH, were evaluated in 31 adults and in 95 children >/=6 months old. rA2cp248/404/1030 Delta SH was subsequently evaluated in 44 infants 1-2 months old. These vaccine candidates share 4 attenuating… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 66 extracted citations

Similar Papers

Loading similar papers…